<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7400054\results\search\testTrace\results.xml">
  <result pre="challenges, and disease mitigation measures. coronavirus pandemic SARS-CoV-2 COVID-19 pathobiology" exact="diagnosis" post="vaccines therapeutics 1. Introduction The ongoing global threat, declared"/>
  <result pre="to the elderly [6]. The average age noted for SARS-CoV-2" exact="infection" post="susceptibility is 55.5 years, while that for the case"/>
  <result pre="drugs, monoclonal therapeutic antibodies, and vaccine candidates. However, many such" exact="treatment" post="options are in the different stages of pre-clinical and"/>
  <result pre="(SARS) and MERS. 2.1. SARS-CoV The first incidence of SARS-CoV" exact="infection" post="was reported on 16 November 2002, in the coastal"/>
  <result pre="province of southeast China bordering Hong Kong and Macau. This" exact="infection" post="spread across 31 countries at a moderate speed. The"/>
  <result pre="this epidemic. After adopting strict public health measures, consisting of" exact="quarantine" post="and the lockdown of air traffic, the disease was"/>
  <result pre="virus transmission [19,23]. 2.3. SARS-CoV-2 The first case of SARS-CoV-2" exact="infection" post="was reported in the first week of December 2019"/>
  <result pre="constantly endorsing and promoting better personal hygiene practices. Social and" exact="physical distancing," post="as well as self-isolation, are recommended to contain the"/>
  <result pre="or low lymphocyte count, and no symptomatic improvement after antimicrobial" exact="treatment" post="for 3 to 5 days following standard clinical guidelines"/>
  <result pre="guidelines [11,54]. The patients presented with a severe acute respiratory" exact="infection" post="and some developed acute respiratory distress syndrome (ARDS) and"/>
  <result pre="through respiratory droplets (&amp;gt;5â€&quot;10 Î¼m in diameter) and fomites. Droplet" exact="infection" post="is associated mainly with coughing, sneezing, and talking to"/>
  <result pre="effectively contain the spread [11,56,57]. There is evidence of intestinal" exact="infection" post="from SARS-CoV-2, and subsequent excretion through feces [56,58]. In"/>
  <result pre="date. Some reports suggest SARS-CoV-2 transmission through semen and the" exact="infection" post="of SARS-CoV-2 in newborns; however, there is no evidence"/>
  <result pre="however, there is no evidence for vertical transmission or intrauterine" exact="infection" post="in a COVID-19 patient during the late pregnancy stage"/>
  <result pre="stage [55]. 7.2. Incubation Period The incubation period for SARS-CoV-2" exact="infection" post="ranged from 2 to 14 days in human-to-human transmission,"/>
  <result pre="diseases, and respiratory system diseases) are highly susceptible to the" exact="infection" post="[25]. Women are less susceptible to SARS-CoV-2 infection than"/>
  <result pre="to the infection [25]. Women are less susceptible to SARS-CoV-2" exact="infection" post="than men and this is possibly due to different"/>
  <result pre="virus load and inflammation. Recently, studies have shown that SARS-CoV-2" exact="infection" post="in children (though less severely affected), may develop the"/>
  <result pre="clear whether Kawasaki disease-like forms are a result of SARS-CoV-2" exact="infection" post="alone or just SARS-CoV-2 induced aggravations in Kawasaki disease"/>
  <result pre="globe. On 31 December 2019, an â€œurgent notice on the" exact="treatment" post="of pneumonia of unknown causeâ€� was issued to the"/>
  <result pre="from COVID-19. The WHO published interim laboratory guidelines for the" exact="detection" post="of SARS-CoV-2 [65]. As of 7 June, 2020, COVID-19"/>
  <result pre="pleuritic chest pain were also observed in rare cases. The" exact="infection" post="more commonly affects people with cardiopulmonary or renal diseases,"/>
  <result pre="on the time of occurrence and intensity of symptoms, the" exact="infection" post="has been categorized into three stages; mild, severe, and"/>
  <result pre="Immunopathobiology Existing literature documents that patients suffering from severe SARS-CoV-2" exact="infection" post="might suffer from the cytokine storm syndrome that could"/>
  <result pre="at a similar point or slightly earlier than in SARS-CoV" exact="infection" post="[86,87]. A recently released antibody profile against SARS-CoV-2 has"/>
  <result pre="against SARS-CoV-2. Increasing evidence suggests that fatalities resulting from SARS-CoV-2" exact="infection" post="could be primarily attributed to the ARDS [90,91], which"/>
  <result pre="MCP1, MIP1Î±, and TNF) from immune effector cells during SARS-CoV-2" exact="infection" post="[91,93,94,95,96,97,98]. In this context, the increased levels of IL-6"/>
  <result pre="were found to be a potential intermediate host. The recent" exact="detection" post="and whole-genome sequence analysis of SARS-CoV-2 from Malayan pangolins"/>
  <result pre="a dog indicates that the dog might have acquired the" exact="infection" post="from infected individuals. These findings suggest low chances of"/>
  <result pre="ongoing search for a suitable animal model to study SARS-CoV-2" exact="infection" post="[104]. After the SARS outbreak, numerous inbred mouse strains"/>
  <result pre="and monkeys [107]. Recently, ferrets have been identified as an" exact="infection" post="and transmission animal model for studying SARS-CoV-2. This finding"/>
  <result pre="stringent conditions, and this can also be used as a" exact="screening" post="tool [109]. Zhang et al. used anal swabs in"/>
  <result pre="swabs than respiratory swabs, especially in the later stages of" exact="infection" post="[60]. 12.2. Diagnostic Technologies Sensitive and specific diagnostic methods"/>
  <result pre="cases of epidemics or pandemics, for the rapid and accurate" exact="diagnosis" post="of viruses. Molecular (RT-PCR) assays are fast, highly sensitive,"/>
  <result pre="China, indicates that widespread and intense testing, combined with strict" exact="quarantine" post="measures for positive and suspected cases, are crucial for"/>
  <result pre="positive and suspected cases, are crucial for combatting SARS-CoV-2. Large-scale" exact="screening" post="is arduous with the currently used molecular tests; therefore,"/>
  <result pre="scenario [111]. In this context, a recent breakthrough in COVID-19" exact="diagnosis" post="was marked by the XpertÂ® Xpress SARS-CoV-2 test (an"/>
  <result pre="automated POCT with EUA from the FDA and enables the" exact="detection" post="of SARS-CoV-2 in the nasal wash, nasopharyngeal swab, and"/>
  <result pre="used at the community level, are likely to improve the" exact="testing" post="capacities, and hence, would be pivotal in disrupting the"/>
  <result pre="of RT-PCR, CRISPR, and metagenomic next-generation sequencing (mNGS) for the" exact="detection" post="of SARS-CoV-2 and confirmed the effective clinical diagnosis of"/>
  <result pre="for the detection of SARS-CoV-2 and confirmed the effective clinical" exact="diagnosis" post="of COVID-19 [115]. 12.3. Artificial Intelligence in COVID-19 Diagnosis"/>
  <result pre="intelligence (AI) tools are being tested and applied for preliminary" exact="screening" post="of possible early infections of SARS-CoV-2 among individuals. Based"/>
  <result pre="made globally to develop safe and effective vaccines against SARS-CoV-2" exact="infection" post="[120]. Approximately 200 vaccine candidates have already been developed"/>
  <result pre="of such a vaccine is its ability to mimic natural" exact="infection" post="to trigger a more potent immune response and rapid"/>
  <result pre="is the repurposing of drugs [12,124]. However, no specific anti-SARS-CoV-2" exact="treatment" post="has been recommended by the US FDA, yet owing"/>
  <result pre="China in February 2020, is commonly used to treat influenza" exact="infection" post="in China and Japan and has shown promising results"/>
  <result pre="has shown promising results in shortening the course of SARS-CoV-2" exact="infection" post="[12,124,125]. This drug acts by inhibiting the RNA-dependent RNA"/>
  <result pre="also a repurposed drug that was initially developed for the" exact="treatment" post="of Ebola virus infection. Remdisivir is reported to prevent"/>
  <result pre="RNA transcription. Currently, remdisivir is under clinical trials for the" exact="treatment" post="of COVID-19 patients. Furthermore, a combination of lopinavir and"/>
  <result pre="failed to serve its initial purpose when used for the" exact="treatment" post="of COVID-19 patients in recent clinical trials in China"/>
  <result pre="antibodies against SARS-CoV-2) could also be used as an alternative" exact="treatment" post="strategy to improve the survival rate of COVID-19 patients"/>
  <result pre="under an emergency investigational new drug protocol (FDA, 2020). The" exact="treatment" post="strategies must focus on curbing hyper inflammation, and the"/>
  <result pre="or are being considered for a clinical trial for the" exact="treatment" post="of COVID-19. Of note, the information provided in this"/>
  <result pre="contain the further spread of the virus by a â€œbig" exact="isolation" post="and big disinfectionâ€� policy during the Chinese spring festival"/>
  <result pre="with emphasis on personal hygiene to curtail transmission. Physical and" exact="social distancing" post="campaigns should be promoted to lessen physical contact and"/>
  <result pre="infected individuals while others remain asymptomatic, and the reappearance of" exact="infection" post="in specific cured individuals, among others. With the availability"/>
  <result pre="well to plan for better immunomodulatory therapies for the effective" exact="treatment" post="and control of COVID-19 infections. Acknowledgments All the authors"/>
  <result pre="immunopathology section; P.G., K.G. and M.P.S. collected material on clinical" exact="diagnosis" post="and clinical profile; M.I.Y., R.T., M.P. and S.K.P. involved"/>
  <result pre="Situation Reportâ€&quot;93Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200422-sitrep-93-covid-19.pdf?sfvrsn=35cf80d7_4(accessed on 23 April 2020) 6.WeiM.YuanJ.LiuY.FuT.YuX.ZhangZ.J.Novel coronavirus" exact="infection" post="in hospitalized infants under 1 year of age in"/>
  <result pre="Med. Res.202071110.1186/s40779-020-00240-032169119 13.HodgsonJ.The pandemic pipelineNat. Biotechnol.20203852353210.1038/d41587-020-00005-z32203293 14.RotheC.SchunkM.SothmannP.BretzelG.FroeschlG.WallrauchC.ZimmerT.ThielV.JankeC.GuggemosW.et al.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN. Engl. J. Med.202038297097110.1056/NEJMc200146832003551"/>
  <result pre="55.ChenH.GuoJ.WangC.LuoF.YuX.ZhangW.LiJ.ZhaoD.XuD.GongQ.et al.Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: A retrospective review of medical"/>
  <result pre="58.HindsonJ.COVID-19: Faecalâ€&quot;oral transmission?Nat. Rev. Gastroenterol. Hepatol.20201725910.1038/s41575-020-0295-732214231 59.XuY.LiX.ZhuB.LiangH.FangC.GongY.GuoQ.SunX.ZhaoD.ShenJ.Characteristics of pediatric SARS-CoV-2" exact="infection" post="and potential evidence for persistent fecal viral sheddingNat. Med.20202650250510.1038/s41591-020-0817-432284613"/>
  <result pre="of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary" exact="infection" post="of miceJ. Immunol.20041734030403910.4049/jimmunol.173.6.403015356152 91.HelmsJ.TacquardC.SeveracF.Leonard-LorantI.OhanaM.DelabrancheX.MerdjiH.Clere-JehlR.SchenckM.GandetF.F.High risk of thrombosis in patients"/>
  <result pre="Dis.2004101293129610.3201/eid1007.03111915324552 106.HoganR.J.GaoG.RoweT.BellP.FliederD.ParagasJ.KobingerG.P.WivelN.A.CrystalR.G.BoyerJ.et al.Resolution of primary severe acute respiratory syndrome-associated coronavirus" exact="infection" post="requires Stat1J. Virol.200478114161142110.1128/JVI.78.20.11416-11421.200415452265 107.RobertsA.VogelL.GuarnerJ.HayesN.MurphyB.ZakiS.SubbaraoK.Severe acute respiratory syndrome coronavirus infection"/>
  <result pre="coronavirus infection requires Stat1J. Virol.200478114161142110.1128/JVI.78.20.11416-11421.200415452265 107.RobertsA.VogelL.GuarnerJ.HayesN.MurphyB.ZakiS.SubbaraoK.Severe acute respiratory syndrome coronavirus" exact="infection" post="of golden Syrian hamstersJ. Virol.20057950351110.1128/JVI.79.1.503-511.200515596843 108.KimY.-I.KimS.-G.KimS.-M.KimE.-H.ParkS.-J.YuK.-M.ChangJ.-H.KimE.J.LeeS.CaselM.A.B.et al.Infection and rapid"/>
  <result pre="transmission of SARS-CoV-2 in ferretsCell Host Microbe202027C704C70910.1016/j.chom.2020.03.023 109.ToK.K.TsangO.T.Chik-Yan YipC.ChanK.H.WuT.C.ChanJ.M.C.LeungW.S.ChikT.S.ChoiC.Y.KandambyD.H.et al.Consistent" exact="detection" post="of 2019 novel coronavirus in salivaClin. Infect. Dis.202010.1093/cid/ciaa14932047895 110.collab:"/>
  <result pre="application of a rapid IGM-IGG combined antibody test for SARS-CoV-2" exact="infection" post="diagnosisJ. Med. Virol.202010.1002/jmv.2572732104917 114.ZhengJ.SARS-CoV-2: An emerging coronavirus that causes"/>
  <result pre="causes a global threatInt. J. Biol. Sci.2020161678168510.7150/ijbs.4505332226285 115.AiJ.W.ZhangY.ZhangH.C.XuT.ZhangW.H.Era of molecular" exact="diagnosis" post="for pathogen identification of unexplained pneumonia, lessons to be"/>
  <result pre="April 2020) 124.GuoD.Old weapon for new enemy: Drug repurposing for" exact="treatment" post="of newly emerging viral diseasesVirol. Sin.202010.1007/s12250-020-00204-732048130 125.MifsudE.J.HaydenF.G.HurtA.C.Antivirals targeting the"/>
  <result pre="COVID-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 129.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: Results of an open-label non-randomized clinical trialInt."/>
  <result pre="Dis.20202039840010.1016/S1473-3099(20)30141-932113510 131.Rubbert-RothA.FurstD.E.NebeskyJ.M.JinA.BerberE.A review of recent advances using tocilizumab in the" exact="treatment" post="of rheumatic diseasesRheumatol. Ther.20185214210.1007/s40744-018-0102-x29502236 132.AdhikariS.P.MengS.WuY.J.MaoY.P.YeR.X.WangQ.Z.SunC.SylviaS.RozelleS.RaatH.et al.Epidemiology, causes, clinical manifestation"/>
  <result pre="154.ContiP.GallengaC.E.TetÃ¨G.CaraffaA.RonconiG.YounesA.ToniatoE.RossR.KritasS.K.How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2)" exact="infection" post="and lung inflammation mediated by IL-1J. Biol. Regul. Homeost."/>
  <result pre="followed by worldwide Treatment/Vaccine Glucocorticoid and Interferon No effective approved" exact="treatment" post="or vaccine Lopinavir/Ritonavir (in testing) Receptor Angiotensin-converting enzyme-2 (ACE-2)"/>
  <result pre="Gilead Sciences, USA Clinical trials are under progress Developed for" exact="treatment" post="of Ebola virus infection Lopinavir + Ritonavir AbbVie, USA"/>
  <result pre="trials are under progress Developed for treatment of Ebola virus" exact="infection" post="Lopinavir + Ritonavir AbbVie, USA Further research is under"/>
 </snippets>
</snippetsTree>
